INTRODUCTION
Calprotectin is a calcium and zincbinding protein, representing more than 60% of the cytosolic proteins in neutrophils. The presence of calprotectin in feces quantitatively relates to neutrophil migration into the gastrointestinal (GI) tract [1]. Therefore, it is considered as a valid marker of intestinal inflammation because it is released during cell activation and death [2] .
As the GI tract of cirrhotic patients shows various alterations of its mucosal barrier including infiltrates of neutrophils, calprotectin might be a promising diagnostic parameter to diagnose the onset and course of hepatic encephalopathy [3] .
There is extensive literature about the diagnostic significance of fecal calprotectin in patients with inflammatory bowel disease, non-steroidal antiinflammatory enteropathy and patients with irritable bowel disease, studies about the value of calprotectin in patients with cirrhosis are extremely sparse [4, 5] . 
Fecal calprotectin in cirrhosis was

RESULTS
The study was conducted on 90 patients (54 male and 36 female), the mean age 49.92±8.86 years (61% of patients were hepatitis C, 45% were hepatitis B).
This study showed statistical significant difference between studied groups regarding age {mean age was highest in group I (52.72±9.03)}. Regarding clinical examination, ascites was more frequent in group I and III (100%) and jaundice was more frequent in group II (76%) .
This study showed statistically significant difference between the studied groups as regard to platelet count ,serum albumin, INR, bilirubin, SGOT As regard MELD score, there was no statistical significant difference between studied groups. But, there was statistical significant difference between diseased groups regarding Child classification [Child C was more frequent in group II (72%)] while child B was more frequent in group III (75%) as shown in Table (2) As regard number connection test. There was statistical significant difference between studied groups: {in group II there were 92 % (grade III: forced termination) in comparison to group I there were 64 % grade (I -II) as shown in . This variation in age may be attributed to the diversity of eitiologies of liver cirrhosis and the impact of the course of disease progression.
As regard to sex, residence and smoking, there were no statistical significant difference between studied groups. This was in accordance with Butterworth [10]. But, this was against Manabendra and his colleagues who reported that incidence of hepatic encephalopathy was more in male than in female [11] .
Regarding clinical examination, jaundice was more present in OHE group (76%) and ascites was more frequent in [MHE group and cirrhotic group (100%)]. This was in agree with Hartmann and his colleagues and Thornton who reported that the incidence of hepatic encephalopathy is increased following the development of ascites and increased degree of jaundice [12,13].
As regarding to hematological criteria, Platelet count showed highly statistical significant difference between studied groups (0.001 Finally, fecal calprotectin may serve as a good screening tool for diagnosis of hepatic encephalopathy.
CONCLUSION
Fecal calprotectin level was shown to be significantly higher in cirrhotic patients in comparison with normal subjects. Fecal calprotectin level was shown to be significantly higher in cirrhotic patients presented with HE in comparison to cirrhotic patients.
